Author

R. Jeselsohn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Dahmani· 1 shared A. Feiglin· 1 shared A. Feit· 1 shared A. Font-Tello· 1 shared A. Nardone· 1 shared A. Ors· 1 shared C. E. Fowler· 1 shared C. Ercan· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dahmani

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

A. Nardone, X. Qui, A. Feiglin, X. Fu, S. Spisak, A. Feit, G. Cohen Feit, Y. Xie, A. Font-Tello, C. Guarducci, F. Hermida Prado, S. Syamala, K. Lim, M. Pun, M. Cornwell, , R. Jeselsohn

This study identifies a unique chromatin state in invasive lobular breast cancer (ILC) driven by FOXA1-ER axis, leading to tamoxifen resistance and poor outcomes.

bioRxiv · Mar 29, 2022Cancer Biology

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells

S. W. Fanning, R. Jeselsohn, V. Dharmarajan, C. G. Mayne, M. Karimi, G. Buchwalter, R. Houtman, W. Toy, C. E. Fowler, M. Laine, K. E. Carlson, T. A. Martin, J. Nowak, J. C. Nwachukwu, D. J. Hosfield, , G. L. Greene

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.

bioRxiv · Apr 23, 2018Cancer Biology